胸腺肽α1、苦参素、病毒唑联合治疗丙型肝炎的临床观察

Clinical observation on thymosin α1 combining with kushenin and virazole in the treatment of hepatitis C.

目的观察胸腺肽α1、苦参素、病毒唑联合治疗丙型肝炎患者的效果。方法治疗组在对照组治疗基础上给予胸腺肽α11.6mg皮下注射2次/w,苦参素600mg静脉滴注1次/d,病毒唑800mg+5%葡萄糖或0.9%盐水250ml液中静脉滴注1次/d,3个月后改为苦参素200mg3次/d口服,病毒唑300mg3次/d口服,疗程6个月。对照组第1个月予以甘利欣150mg+5%葡萄糖或0.9%盐水250ml,丹参注射液250ml静点1次/d,此后改为口服维生素类药物一般护肝。随访3个月。结果ALT复常率:治疗结束时,治疗组为81.5%、对照组为44.0%。两组结果显著差异(P<0.01);随访结束3个月时:治疗组80.0%、对照组40.0%,两组结果显著差异(P<0.01)。HCVRNA治疗结束时:治疗组转阴率44.2%、对照组1.1%;随访3个月结束时:治疗组转阴率67.3%、对照组1.6%,两组结果显著差异(P<0.01)。结论胸腺肽α1、苦参素、病毒唑联合治疗丙型肝炎相对安全、有效,可应用于丙型肝炎的抗病毒治疗。

Objective To observe the curative effects of thymosin α1 combining with kushenin and rib-avirin in the treatment of patients with hepatitis C. Methods On the basis of treatment for control group, ex-perimental group was given thymosin α1 subcutaneously at a dose of 1.6mg twice a week,kushenin intra-venously 600mg once a day, ribavirin injection（800mg into 5% G.S or 0.9% N.S 250ml） intravenous drip once a day. Three months later, both kushenin and ribavirin were changed to oral three times a day for 6 months at a dose of 200mg and 300mg respectively. The control group was given diammonium glycyrrihizinate injection （150mg into 5% G.S or 0.9% N.S 250ml） and Dan shen injection 250ml once a day at the first month, then took general vitamin drugs orally for liver protection and follow-up for three months. Results After the treat-ment, the ratio of ALT normalization in experimental group and control group was 81.5% and 44% respec-tively, there had significant differences between two groups（P...更多〈0.01）. At the end of three months follow-up, the ratio of ALT normalization in experimental group and control group was 80.0% and 40.0% respectively, there also had significant differences between the two groups（P〈0.01）. After the treatment, the ratio of HCV RNA result turned to negative in experimental group and control group was 44.2% and 1.1% respectively. At the end of three months follow-up, the ratio difference of HCV RNA result turn to negative between exper-imental group and control group was 67.3% and 1.6%, there had significant differences between two groups （P〈0.01）. Conclusion Combining use of Thymosin α1 with kushenin and ribavirin in the treatment of hep-atitis C was relatively safe and effective and could be used in the anti-virus treatment of hepatitis C.